ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?

por Petrov, Dmitry, Mansfield, Colin, Moussy, Alain, Hermine, Olivier
Publicado 2017

Neuroprotective effect of masitinib in rats with postischemic stroke

por Kocic, Ivan, Kowianski, Przemyslaw, Rusiecka, Izabela, Lietzau, Grazyna, Mansfield, Colin, Moussy, Alain, Hermine, Olivier, Dubreuil, Patrice
Publicado 2014

Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial

por Vermersch, Patrick, Brieva-Ruiz, Luis, Fox, Robert J., Paul, Friedemann, Ramio-Torrenta, Lluis, Schwab, Matthias, Moussy, Alain, Mansfield, Colin, Hermine, Olivier, Maciejowski, Maciej
Publicado 2022

Masitinib Combined with Standard Gemcitabine Chemotherapy: In Vitro and In Vivo Studies in Human Pancreatic Tumour Cell Lines and Ectopic Mouse Model

por Humbert, Martine, Castéran, Nathalie, Letard, Sébastien, Hanssens, Katia, Iovanna, Juan, Finetti, Pascal, Bertucci, François, Bader, Thomas, Mansfield, Colin D., Moussy, Alain, Hermine, Olivier, Dubreuil, Patrice
Publicado 2010

Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial

por Dubois, Bruno, López‑Arrieta, Jesús, Lipschitz, Stanley, Doskas, Triantafyllos, Spiru, Luiza, Moroz, Svitlana, Venger, Olena, Vermersch, Patrick, Moussy, Alain, Mansfield, Colin D., Hermine, Olivier, Tsolaki, Magda
Publicado 2023

Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial

por Dubois, Bruno, López-Arrieta, Jesús, Lipschitz, Stanley, Triantafyllos, Doskas, Spiru, Luiza, Moroz, Svitlana, Venger, Olena, Vermersch, Patrick, Moussy, Alain, Mansfield, Colin D., Hermine, Olivier, Tsolaki, Magda
Publicado 2023

Long-term survival analysis of masitinib in amyotrophic lateral sclerosis

por Mora, Jesus S., Bradley, Walter G., Chaverri, Delia, Hernández-Barral, María, Mascias, Javier, Gamez, Josep, Gargiulo-Monachelli, Gisella M., Moussy, Alain, Mansfield, Colin D., Hermine, Olivier, Ludolph, Albert C.
Publicado 2021

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study

por Tebib, Jacques, Mariette, Xavier, Bourgeois, Pierre, Flipo, René-Marc, Gaudin, Philippe, Le Loët, Xavier, Gineste, Paul, Guy, Laurent, Mansfield, Colin D, Moussy, Alain, Dubreuil, Patrice, Hermine, Olivier, Sibilia, Jean
Publicado 2009

Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial

por Davidescu, Lavinia, Ursol, Grigoriy, Korzh, Oleksii, Deshmukh, Vikranth, Kuryk, Lesia, Nortje, Monja-Marie, Godlevska, Olga, Devouassoux, Gilles, Khodosh, Eduard, Israel, Elliot, Moussy, Alain, Mansfield, Colin D, Hermine, Olivier, Chanez, Pascal
Publicado 2022

Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT

por Dubreuil, Patrice, Letard, Sébastien, Ciufolini, Marco, Gros, Laurent, Humbert, Martine, Castéran, Nathalie, Borge, Laurence, Hajem, Bérengère, Lermet, Anne, Sippl, Wolfgang, Voisset, Edwige, Arock, Michel, Auclair, Christian, Leventhal, Phillip S., Mansfield, Colin D., Moussy, Alain, Hermine, Olivier
Publicado 2009

Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology

por Hammam, Kahina, Saez-Ayala, Magali, Rebuffet, Etienne, Gros, Laurent, Lopez, Sophie, Hajem, Berengere, Humbert, Martine, Baudelet, Emilie, Audebert, Stephane, Betzi, Stephane, Lugari, Adrien, Combes, Sebastien, Letard, Sebastien, Casteran, Nathalie, Mansfield, Colin, Moussy, Alain, De Sepulveda, Paulo, Morelli, Xavier, Dubreuil, Patrice
Publicado 2017